<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5249">
  <stage>Registered</stage>
  <submitdate>6/01/2015</submitdate>
  <approvaldate>6/01/2015</approvaldate>
  <nctid>NCT02338245</nctid>
  <trial_identification>
    <studytitle>Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab</studytitle>
    <scientifictitle>Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ASLAN001-003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic Breast Cancer</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ASLAN001
Treatment: drugs - Lapatinib
Treatment: drugs - Capecitabine

Experimental: Treatment Arm A - ASLAN001 + Capecitabine

Active Comparator: Treatment Arm B - Lapatinib + Capecitabine


Treatment: drugs: ASLAN001
ASLAN001 400mg BID

Treatment: drugs: Lapatinib
Lapatinib 1250mg QD

Treatment: drugs: Capecitabine
Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare the efficacy of ASLAN001 in combination with capecitabine, to lapatinib in combination with capecitabine in the percentage change from baseline tumor size at Week 12</outcome>
      <timepoint>Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety for all metastatic breast cancer (MBC) subjects (Physical examination, body weight, vital signs, ECG parameter, hematology, clinical laboratory tests and Adverse Events) - Physical exam, body weight, vital signs (Blood pressure, respiratory rate and body temperateure), ECG parameter, hematology, clinical laboratory tests (clinical chemistry, coagulation and urinalysis) and Adverse Events (AEs)/ Serious Adverse Events (SAEs)</outcome>
      <timepoint>estimated 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To further compare the efficacy of ASLAN001 in combination with capecitabine to lapatinib in combination with capecitabine, as measured by PFS and tumor volume</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To further compare the efficacy of ASLAN001 in combination with capecitabine to lapatinib in combination with capecitabine, as measured by the Objective Response Rate (ORR), Duration of Response (DoR), and Overall Survival (OS) - Composite outcome measures</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients with documented histological confirmation of breast cancer with HER 2
             overexpression or gene amplification prior to study entry.

          -  Patients with HER 2-positive metastatic breast cancer that have failed on prior first
             line treatment with trastuzumab or who have progressed within 1 year of treatment with
             trastuzumab in adjuvant setting.

          -  Presence of at least one radiographically measurable disease (bone metastases and
             ascites are not considered measurable lesions).

          -  Patients of the respective country's legal age or older at the time of written
             informed consent.

          -  Patients with acceptable organ and hematological function</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients with radiation treatment or major surgical procedures within 21 days prior to
             study entry.

          -  Patients with malabsorption syndrome, diseases significantly affecting
             gastrointestinal function, resection of the stomach or small bowel, or difficulty in
             swallowing and retaining oral medications.

          -  Patients with an uncontrolled intercurrent illness including, but not limited to,
             ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, diabetes,
             hypertension, or psychiatric illness/social situations that would limit compliance
             with study requirements.

          -  Patients with any history of other malignancy unless in remission for more than 1
             year. (Nonmelanoma skin carcinoma and carcinoma-in-situ of uterine cervix treated with
             curative intent is not exclusionary).

          -  Patients with symptomatic central nervous system metastasis and/or on systemic
             steroids or anticonvulsants within 3 months before the first dose of randomized
             therapy.

          -  Patients who are pregnant or breast-feeding.

          -  Patients who were previously treated with ASLAN001 and/or with lapatinib.

          -  Patients who have received more than 2 lines of any therapies in metastatic stage.

          -  Patients who have received any investigational drug (or have used an investigational
             device) within 21 days or received any antineoplastic monoclonal antibodies within a
             period of 5 half-lives before receiving the first dose of randomized therapy.

          -  Patients with unresolved or unstable serious toxicity from prior administration of
             another investigational drug and/or prior cancer treatment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>29/12/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>25/08/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Australia - Western Australia</hospital>
    <postcode>6000 - Western Australia</postcode>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Bacolod City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Dasmarinas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taoyuan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>KaohSiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Aslan Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an open-label, randomized, parallel group Phase 2A/2B study to evaluate the clinical
      activity of ASLAN001 in combination with capecitabine compared with lapatinib in combination
      with capecitabine in patients with HER2 positive metastatic breast cancer that has failed on
      prior trastuzumab therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02338245</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>